Donor lymphocyte infusions (DLI) are used to resolve mixed T-cell chimerism (TCC) after allo-SCT despite a substantial risk of GVHD. We analyzed the impact of prophylactic CD8-depleted (CD8 depl ) DLI in 20 recipients of anti-CD52 alemtuzumab in vivo T-cell-depleted allografts with declining donor TCC after day þ 60. A total of 13 patients received CD8
Introduction
Donor lymphocyte infusions (DLI) are used to treat recurrent disease after allogeneic hematopoietic SCT. [1] [2] [3] They are also applied preemptively for mixed hematopoietic chimerism after non-myeloablative or T-cell-depleted (TCD) conditioning. [4] [5] [6] [7] However, the benefit from DLI is hampered by the risk of inducing GHVD in 40-60% of recipients. 2, 8 Previous studies have shown that the removal of CD8-positive T cells from DLI might reduce the risk of GVHD, while preserving beneficial DLI effects. 9 , 10 Here, we report that DLI, extensively depleted of CD8-positive T cells, reliably convert patients with declining T-cell chimerism (TCC) to full donor chimeras. In addition, we show that these DLI restore the predominance of the CD52-positive compartment among the donor CD4-positive T cells, which is profoundly impaired after in vivo T-cell depletion by the anti-CD52 Ab alemtuzumab.
Patients, materials and methods

Patients
Patients with hematological malignancies received unmanipulated PBSCs after a reduced-intensity conditioning with fludarabine, melphalan and in vivo T-cell depletion by alemtuzumab. 11 In the absence of GVHD, immunosuppressive treatment was discontinued. Subsequently, dose-escalated CD8-depleted (CD8 depl ) DLI at 1, 3 and 10 Â 10 6 CD4-positive T cells per kg body weight were administered prophylactically at 60-90-day intervals independent of chimerism status. The first dose of DLI was given between 60 and 182 days post-transplantation provided that immunosuppressive medication was completely tapered. DLI were not administered in the presence of active spontaneous GVHD. In addition, any further DLI dose was stopped after a previous episode of DLI-associated GVHD grade 2 or higher. Some patients did not receive DLI, because their donors were not available for a second donation. Herein, we report on 20 patients transplanted in this protocol who experienced a secondary loss of donor TCC. Their characteristics are outlined in Table 1 . Acute GVHD was scored according to the Glucksberg criteria.
12
CD8-depletion procedure CD8-depletion of unmobilized donor leukaphereses was performed using the CliniMACS Plus Instrument (Miltenyi Biotec, Bergisch Gladbach, Germany). As recently described, this procedure leads to a 2.5-6-log reduction of CD8-positive T cells in the DLI preparation. 13 Briefly, the leukapheresis product was diluted 1:3 in CliniMACS PBS/EDTA buffer and was centrifuged at 300 g. The cell pellet was resuspended in 95 ml buffer and 7.5 ml CliniMACS CD8 reagent (Miltenyi Biotec) was added. Subsequently, the leukapheresis product was rotated for 30 min at 21 1C. After adjusting the product to 4 Â 10 8 cells/ml, the leukapheresis bag was connected to a CliniMACS Tubing Set LS and depletion was performed using the 'DEPLETION 2.1' program (software version 2.31). The CD8 depl target fraction was aliquoted according to CD4-positive T cells per kg body weight of the patient and cryopreserved in liquid nitrogen until use.
Flow cytometry
Cells were incubated for 15 min at 4 1C with FITC-, phycoerythrin, phycoerythrin-cyanin 5 or phycoerythrincyanin 7-conjugated MoAbs specific for the indicated CD Ags. FACS Abs were from Beckman Coulter (Krefeld, Germany), except for anti-CD3-allo-phycocyanine, anti-CD45-FITC (both from Miltenyi Biotec) and anti-CD52-FITC/phycoerythrin (Serotec, Duesseldorf, Germany). FACS analyses were performed on flow cytometer BD FACSCanto (BD Biosciences, Heidelberg, Germany). Gating of viable lymphocytes or monocytes was performed according to forward and sideward scatters.
Cell sorting and chimerism analysis CD3-positive cells were selected from peripheral blood using Whole Blood MicroBeads and the Automacs device (Miltenyi Biotec). Purity was confirmed to be X90% by flow cytometry. For the analysis of CD52-positive and CD52-negative T-cell subsets, cells were sorted by flow cytometry using the FACSAria instrument with FACSDiva software (BD Biosciences). Chimerism was analyzed by STR-technique as described. 13 In samples with low cell yield, an alternative STR-assay was used. 14 
Results and discussion
We recently described the feasibility of applying CD8 depl DLI in a prophylactic setting to improve immune reconstitution after TCD allogeneic hematopoietic SCT. 13 In the previous study, we introduced four patients who developed a secondary loss of donor TCC that was converted back to full donor TCC after CD8 depl DLI. In the current report, we show the results of a more comprehensive analysis of lineage-specific chimerism in Table 1 Patients further patients following the same transplantation protocol. We identified 20 individuals with late mixed TCC beyond day þ 60, including the four patients from our previous publication (patients 1-4, Table 1 ). A total of 13 of these patients qualified for prophylactic CD8 depl DLI starting between day þ 60 and þ 182 (median, day þ 126). Seven mixed T-cell chimeras did not receive DLI, because they had acute GVHD (n ¼ 4) or because their donors were not available (n ¼ 3). After a median observation time of 19 months (range, 5-22 months), 3 patients of the DLI-group relapsed with their underlying malignancies and 2 of them subsequently died. One additional patient died from infection. Of the non-DLI-group, four patients died from disease relapse. Among them, all were GVHD-free patients who did not receive DLI, because their donors were unavailable. One further patient with spontaneous GVHD died from infection. The patients' characteristics are outlined in Table 1 . CD8 depl DLI were followed by acute GVHD of grade II-III and severe chronic GVHD in five and two patients, respectively ( Table 2 ). The patient who developed grade III acute GVHD after the second DLI dose had been transplanted from an HLA-mismatched unrelated donor. The incidence of acute GVHD exceeding grade I was seen in 5 of 13 (38%) and thereby higher than in previous reports. 15, 16 However, none of these previous trials applied DLI as early as in the first 3 to 4 months after transplantation. The reduction of the DLI dose might lead to a reduced induction of GVHD, as has been recently shown for the early prophylactic application of CD8 depl DLI in the haploidentical setting. 17 In addition, the design of our clinical trial included a DLI dose escalation, and occurrence of GVHD was the major stopping criteria. Therefore, a higher rate of GVHD was inherent to the protocol. Future studies comparing CD8 depl and unmani- depl DLI. Days of DLI are labelled by arrows. The second group of three patients did not receive DLI because of unavailable donors and the third group of four patients did not receive DLI because of spontaneous acute GVHD. The proportion of donor TCC is indicated by the following symbols: X95% donor; 66-94% donor; 35-65% donor; and 6-34% donor. The small numbers next to circles indicate the lowest percentage of donor TCC for the individual patient. %, Transient acute GVHD; , extensive chronic GVHD; (a), day of disease relapse; and (w), day of death. pulated DLI to convert a loss of TCC may, therefore, start at a lower T-cell dose and stop as soon as TCC has converted to complete donor.
As shown in Figure 1 , all 13 patients of the DLI group showed a significant increase of donor TCC after CD8 depl DLI, with 12 of them converting to durable complete T-cell chimeras. Interestingly, three of these patients converted to full TCC after the initiation of immunosuppressive therapy for DLI-induced GVHD (Table 2) . Thus, we found no evidence that immunosuppressive treatment impedes the development of full donor TCC after CD8 depl DLI. In contrast, only one of four patients (P19) who did not receive DLI because of acute GVHD spontaneously converted to full donor TCC. In addition, none of the three patients who did not receive DLI because of donor unavailability became full donor chimeras, although they had been tapered off immunosuppressive treatment as scheduled.
The predictive value of donor TCC after allogeneic hematopoietic SCT is still controversial. Several investigators showed an association of early full donor TCC with an enhanced risk of GVHD, 18, 19 and a positive correlation of low donor TCC with an increased probability of disease relapse and graft rejection after T-cell-replete reducedintensity protocols. [20] [21] [22] [23] Many of these associations may depend on the underlying disease and the conditioning regimen. 21 Conflicting data exist, particularly for protocols involving T-cell depletion, in which mixed TCC has been associated with higher incidence of disease relapse 24 Figure 2 CD52 expression of lymphocytes before and after CD8 depl donor lymphocyte infusion (DLI). Lymphocytes of a patient receiving three doses of CD8 depl DLI during the first year after transplantation were analyzed for the expression levels of CD52. The plots were gated on lymphocytes with regard to forward and sideward scatters, and further gated as outlined in the figure. On day þ 110 before the first dose of DLI, the majority of CD8 and CD4 T cells was CD52-negative. DLI therapy was followed by increased proportions of CD52-positive T cells in both subsets at day þ 350. The positive CD52 status of B cells (CD3 À /CD19 þ ) and NK cells (CD3 À /CD56 þ ) remained unchanged over time.
also with higher disease-free survival because of lower transplant-related mortality. 25, 26 Nevertheless, most TCD patients with mixed TCC have been treated preemptively with DLI to prevent graft rejection and disease relapse, although with a significant risk of severe GVHD. 27 Our study shows that mixed TCC occurring after TCD allo-transplantation can be reliably converted to full donor TCC by CD8 depl DLI. Most interestingly, we observed successful conversion even in cases with donor TCC of less than 20%, a threshold below which unmanipulated DLIs have been shown to be of poor efficacy. 6 This finding might be explained by more selective immune reactions of donorderived CD4 T cells recognizing allo-peptides on HLA class II molecules that are preferentially expressed by recipient hematopoietic cells, but not by epithelial cells under noninflammatory conditions. 28 In addition, the absolute T-cell counts after alemtuzumab-based conditioning are significantly lower than that after T-cell-replete transplantation, which might facilitate the influence of DLI-derived T cells on donor TCC. Data from small trials so far suggest that CD8 depl DLI might induce comparably low rates of GVHD, while retaining the beneficial DLI activity. 9, 10, 13, 29 However, randomized trials designed to investigate the impact of CD8 depletion on DLI effects in large patient cohorts are warranted to answer that question.
We have shown, in our previous report, that CD8 depl DLI increased the numbers of CD4-positive T cells in peripheral blood. 13 When we analyzed the phenotype of reconstituting lymphocytes, we detected a substantial proportion of CD52-negative T cells, preferentially among the CD4 and to a lesser extent among the CD8-positive subset. In contrast, CD52-negative populations were not observed in monocytes (not shown), B cells and NK cells (Figure 2) . We followed the CD52 status on CD4-positive and CD8-positive T cells of patients with and without CD8 depl DLI. Significantly higher percentages of CD52-positive CD4-positive T cells were found after DLI (Figure 3) . Although an increased proportion of CD52-positive CD8-positive cells was also observed after DLI in individual patients (Figure 2 ), this effect did not reach statistical significance when comparing larger populations of DLI and non-DLI patients (Figure 3) . The lack of increase in the proportion of CD52-positive CD8-positive T cells, considering the complete CD8 depl DLI cohort, is most likely related to a low number of transferred CD8-positive T cells in the DLI preparation. However, the in vivo expansion of individual CD8-positive T-cell clones in response to allo-Ags or pathogens might have contributed to the increase of CD52-positive CD8-positive T cells in single patients, as in the one outlined in Figure 2 . In non-DLI patients, substantial proportions of CD4-positive T cells remained CD52-negative beyond the first year after hematopoietic SCT. This is long after the anti-CD52 Ab alemtuzumab has been shown to fall below pharmacologically active serum concentrations. 30 Transient proliferation of CD52-negative T cells after cross-linking, and subsequent downregulation of CD52 by alemtuzumab has been observed in patients treated for chronic lymphocytic leukemia. 31 Our data are the first to describe long-term persistence of substantial CD52-negative T-cell populations after alemtuzumab-mediated TCD transplantation. They also indicate that CD52 can be used as a marker to track the re-population of the T-cell repertoire with exogenously administered CD52-positive T cells of donor origin.
In conclusion, we show herein that CD8 depl DLI can be used to reliably convert mixed to full donor TCC after TCD allotransplantation. As the rate of GVHD after CD8 depl DLI appears to be lower than that after unmanipulated DLI, 29 the preemptive treatment of decreasing donor TCC with both DLI preparations should be compared in a prospective randomized trial. Whether CD52-negative donor T cells generated by alemtuzumab conditioning differ in function from their CD52-positive counterparts is yet unknown. However, the expansion of adoptively transferred CD4-positive T cells can be readily shown by CD52 co-staining in this setting.
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